跳至主要內容
HR+/HER2- mBC Online Consensus
搜尋
Treatment Algorithm ( Consensus Statement )
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Treatment Algorithm ( Consensus Statement )
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Consensus Statements
Risk Evaluation & Biomarker Testing
Selection of First-Line Treatment
Selection of Second-LINE Treatment(I)
Selection of Second-Line Treatment (II)
Treatment Options Other Than Endocrine-Based Approaches(I)
Consensus Statements
Risk Evaluation & Biomarker Testing
Selection of First-Line Treatment
Selection of Second-LINE Treatment(I)
Selection of Second-Line Treatment (II)
Treatment Options Other Than Endocrine-Based Approaches(I)
Treatment Algorithm ( Consensus Statement )
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Treatment Algorithm ( Consensus Statement )
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Consensus Statements
Risk Evaluation & Biomarker Testing
Selection of First-Line Treatment
Selection of Second-LINE Treatment(I)
Selection of Second-Line Treatment (II)
Treatment Options Other Than Endocrine-Based Approaches(I)
Consensus Statements
Risk Evaluation & Biomarker Testing
Selection of First-Line Treatment
Selection of Second-LINE Treatment(I)
Selection of Second-Line Treatment (II)
Treatment Options Other Than Endocrine-Based Approaches(I)
HR+/HER2–: Endocrine Sensitive
De novo or PD > 12 months after completing adjuvant ET
Investigational therapy
Biomarker-guided therapy
